摘要:
Substituted pyridines and 2-oxo-1,2-dihydropyridines are prepared by reaction of correspondingly substituted halogenobenzenes with tetrazolylboronic acids. The substituted pyridines and 2-oxo-1,2-dihydropyridines according to the invention can be employed as active compounds in medicaments, in particular for the treatment of arterial hypertension and atherosclerosis.
摘要:
Substituted mono- and bipyridylmethylpyridones are prepared either by reaction of pyridones with mono- or bipyridylmethylhalogen compounds or by reaction of pyridone-substituted halogenopyridines with tetrazolylphenylboronic acids. The substituted mono- and bipyridylmethylpyridones can be employed as active compounds in medicaments, in particular for the treatment of arterial hypertension and atherosclerosis.
摘要:
Blood-sugar-lowering dihydropyridines of the formula ##STR1## in which R.sup.1 represents phenyl, naphthyl, thienyl, pyridyl, chromenyl or thiochromenyl, it being possible for the radicals mentioned each to carry up to 2 identical or different substituents from the series comprising halogen, alkyl, alkoxy and alkylthio with in each case up to 6 carbon atoms, fluoroalkyl and fluoroalkoxy with in each case up to 3 carbon atoms and 3 fluorine atoms, nitro and cyano,R.sup.2 represents straight-chain, branched or cyclic alkyl which has up to 8 carbon atoms, can be interrupted in the alkyl chain by an oxygen or a sulphur atom and can be substituted by halogen, phenyl, cyano, hydroxyl, amino, alkylamino or dialkylamino with in each case up to 3 carbon atoms per alkyl group or by N-benzylmethylamino,R.sup.3 represents straight-chain, branched or cyclic alkyl which has up to 6 carbon atoms, can be interrupted in the alkyl chain by an oxygen atom and can be substituted by halogen, hydroxyl, amino, phenyl, morpholino, carboxy or alkoxycarbonyl with up to 4 carbon atoms andR.sup.4 and R.sup.5 each represent hydroxyl, orR.sup.4 and R.sup.5 together represent --O--,or a physiologically acceptable salt thereof.
摘要:
Novel blood sugar-lowering dihydropyridinelactones of the formula ##STR1## in which R represents halogen, C.sub.1 -C.sub.10 -alkyl, C.sub.1 -C.sub.10 -alkoxy, C.sub.1 -C.sub.10 -alkylthio, C.sub.1 -C.sub.10 -alkylsulphinyl, C.sub.1 -C.sub.10 -alkylsulphonyl, cyano, C.sub.1 -C.sub.6 - mono- or polyfluoroalkyl, C.sub.1 -C.sub.6 -mono- or polyfluoroalkoxy or nitro,R.sup.1 represents hydrogen, halogen or C.sub.1 -C.sub.10 -alkyl or C.sub.1 -C.sub.10 -alkoxy,R.sup.2 represents a C.sub.1 -C.sub.20 hydrocarbon radical which can optionally be interrupted or substituted,R.sup.3 represents hydrogen NH.sub.2, CHO, CN or a C.sub.1 -C.sub.6 hydrocarbon radical which can be interrupted in the chain, andR.sup.4 represents a C.sub.1 -C.sub.10 -alkyl or C.sub.2 -C.sub.10 -alkenyl radical which can optionally be interrupted or substituted with the proviso that R is not CF.sub.3 if R.sup.2 represents C.sub.2 H.sub.5.
摘要:
Blood sugar levels are reduced by administration of novel 4-thienyl-dihydropyridines of the formula ##STR1## in which R.sup.1 represents 1 or 2 halogen atoms, or represents straight-chain, branched or cyclic alkyl with up to 8 carbon atoms,R.sup.2 represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical which has up to 15 carbon atoms, is optionally interrupted by one or two oxygen atoms, -N-phenyl or --SO.sub.n -- (n=0, 1 or 2) and is optionally substituted by halogen, phenyl, hydroxyl, cyano, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, pyridyl, piperidino, N-phenylpiperazino, N-methylpiperazino, morpholino or N-benzyl-N-methyl-amino,R.sup.3 represents hydrogen, or represents straight-chain, branched or cyclic alkyl which has up to 6 carbon atoms and is optionally substituted by halogen, hydroxyl, amino or amino-C.sub.1 -C.sub.6 -alkoxy, or represents cyano or formyl andR.sup.4 represents hydrogen or a straight-chain, branched or cyclic alkyl radical which has up to 10 carbon atoms, is optionally interrupted by one or two oxygen atoms in the chain and is optionally substituted by halogen, cyano, hydroxyl, phenyl, carboxyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, amino, C.sub.1 14 C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, formyl, piperidino, morpholino or thiomorpholino, or physiologically acceptable salts thereof.
摘要:
Blood sugar levels are reduced by administration of novel 4-thienyl-dihydropyridines of the formula ##STR1## in which R.sup.1 represents 1 or 2 halogen atoms, or represents straight-chain, branched or cyclic alkyl with up to 8 carbon atoms,R.sup.2 represents a straight-chain, branched or cyclic, saturated or unsaturated hydrocarbon radical which has up to 15 carbon atoms, is optionally interrupted by one or two oxygen atoms, -N-phenyl or --SO.sub.n --(n=0, 1 or 2) and is optionally substituted by halogen, phenyl, hydroxyl, cyano, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, pyridyl, piperidino, N-phenylpiperazino, N-methylpiperazino, morpholino or N-benzyl-N-benzyl-N-methyl-amino,R.sup.3 represents hydrogen, or represents straight-chain, branched or cyclic alkyl which has up to 6 carbon atoms and is optionally substituted by halogen, hydroxyl, amino or amino-C.sub.1 -C.sub.6 -alkoxy, or represents cyano or formyl andR.sup.4 represents hydrogen or a straight-chain, branched or cyclic alkyl radical which has up to 10 carbon atoms, is optionally interrupted by one or two oxygen atoms in the chain and is optionally substituted by halogen, cyano, hydroxyl, phenyl, carboxyl, C.sub.1 -C.sub.6 -alkoxycarbonyl, amino, C.sub.1 -C.sub.6 -alkylamino, di-C.sub.1 -C.sub.6 -alkylamino, formyl, piperidino, morpholino or thiomorpholino,or physiologically acceptable salts thereof.
摘要:
Reducing blood sugar with the novel dihydropyridinelactols, or salts thereof, of the formula ##STR1## in which R.sup.1 represents a phenyl, naphthyl, thienyl, pyridyl, chromonyl, thiochromonyl or thiochromenyl radical, the stated radicals optionally containing 1 or 2 identical or different substituents from the group consisting of fluorine, chlorine and bromine, alkyl, alkoxy and alkylthio, each having 1 to 6 carbon atoms, and fluoroalkyl or fluoroalkoxy, each having up to 3 carbon atoms and 3 fluorine atoms, and nitro and cyano,R.sup.2 represents a straight-chain, branched or cyclic alkyl having up to 12 carbon atoms which is optionally interrupted by 1 or 2 oxygen or sulphur atoms and which is optionally substituted by fluorine, chlorine, phenyl, cyano, hydroxyl, amino, C.sub.1 -C.sub.3 -alkylamino, di-C.sub.1 -C.sub.3 -alkylamino or N-benzylmethylamino,R.sup.3 represents cyano or straight-chain or branched alkyl which has up to 4 carbon atoms and is optionally interrupted in the chain by N-C.sub.1 -C.sub.3 -alkyl and/or oxygen, andR.sup.4 represents straight-chain, branched or cyclic alkyl which has up to 6 carbon atoms and is optionally interrupted by 1 or 2 oxygen atoms and is substituted by one or more radicals from amongst fluorine, chlorine, hydroxyl, phenyl, amino, carboxyl and C.sub.1 -C.sub.4 -alkoxycarbonyl.
摘要:
Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.
摘要:
Substituted tetrahydro-naphthalenes and analogous compounds are prepared by reducing or condensing appropriate functional substituents in substituted tetrahydro-naphthalenes and analogous compounds by customary methods and converting functional groups in this manner into the desired groups. The compounds according to the invention are suitable for use as active compounds in pharmaceuticals, in particular in pharmaceuticals for treating arteriosclerosis and also dyslipidaemias.
摘要:
Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.